Retinal ganglion cells (RGCs) are the sole output neurons of the retina, transmitting visual information from photoreceptors to the brain via their axons in the optic nerve. In Leber hereditary optic neuropathy (LHON), RGCs—particularly the small-caliber fibers of the papillomacular bundle—undergo selective degeneration due to mitochondrial Complex I dysfunction caused by primary mtDNA mutations.
RGCs are located in the ganglion cell layer of the retina and receive synaptic input from bipolar and amacrine cells in the inner plexiform layer. Their axons form the nerve fiber layer before converging at the optic disc to form the optic nerve[1].
Key RGC subtypes:
The papillomacular bundle contains the smallest RGC axons and projects from the macula (region of highest visual acuity) directly to the temporal side of the optic disc. This bundle is preferentially vulnerable in LHON[2].
RGC axons project via the optic nerve, chiasm, and tract to:
Three primary mtDNA mutations account for >90% of LHON cases[3]:
| Mutation | Gene | Protein | Frequency | Recovery Rate |
|---|---|---|---|---|
| m.11778G>A | MT-ND4 | ND4 subunit | 50-70% | 4-22% |
| m.3460G>A | MT-ND1 | ND1 subunit | 15-25% | 22-40% |
| m.14484T>C | MT-ND6 | ND6 subunit | 10-15% | 37-65% |
All three mutations affect Complex I (NADH:ubiquinone oxidoreductase) subunits, impairing electron transport and oxidative phosphorylation.
Complex I deficiency: Mutations reduce electron flux through Complex I, decreasing ATP production and increasing electron leak to molecular oxygen[4].
Oxidative stress: Elevated reactive oxygen species (ROS) damage mitochondrial membranes, proteins, and DNA, creating a feed-forward cycle of mitochondrial dysfunction.
Apoptosis: Energy failure and ROS activate the intrinsic apoptotic pathway via cytochrome c release and caspase-9/caspase-3 activation[5].
Axonal transport disruption: ATP depletion impairs kinesin- and dynein-mediated transport, causing accumulation of damaged organelles and proteins in RGC axons.
The preferential degeneration of papillomacular bundle axons in LHON reflects multiple factors:
LHON is a mitochondrial genetic disorder characterized by acute or subacute bilateral vision loss, typically affecting young adults (peak onset 20-30 years). The male-to-female ratio is approximately 4:1, suggesting modifying factors beyond mtDNA mutations[6].
Clinical features:
Natural history: Visual acuity typically declines to 20/200 or worse within weeks to months. Spontaneous recovery occurs in some patients, particularly those with the m.14484T>C mutation.
RGC involvement occurs in other mitochondrial diseases:
LHON shares features with other neurodegenerative conditions affecting the visual system[7]:
| Condition | Pathology | Visual Manifestation |
|---|---|---|
| Alzheimer disease | Aβ plaques, tau NFTs | Reduced contrast sensitivity, visual field defects |
| Parkinson disease | α-synuclein inclusions | Color vision deficits, reduced visual acuity |
| Glaucoma | RGC apoptosis | Peripheral vision loss, optic disc cupping |
| Dominant optic atrophy | OPA1 mutations | Progressive bilateral vision loss |
The selective vulnerability of specific neuronal populations to mitochondrial dysfunction in LHON parallels the selective degeneration seen in Parkinson disease (dopaminergic neurons) and ALS (motor neurons).
Idebenone is a short-chain benzoquinone that bypasses Complex I by shuttling electrons directly to Complex III. Clinical trials demonstrated benefit in a subset of LHON patients[8]:
RHODOS trial: 85 patients randomized to idebenone 900 mg/day vs placebo for 24 weeks. While the primary endpoint (visual recovery) was not met, post-hoc analysis showed benefit in patients with discordant visual acuity between eyes.
Regulatory status: Approved for LHON in Europe and Israel (Raxone); not FDA-approved in the United States.
AAV-mediated delivery of wild-type ND4 to RGCs has shown promise in early-phase clinical trials[9]:
Approach: Intravitreal injection of AAV2 carrying the nuclear-encoded ND4 gene with a mitochondrial targeting sequence.
Challenges: Importing DNA into mitochondria; immune responses to AAV capsid; optimal timing relative to disease onset.
Optical coherence tomography (OCT): Demonstrates retinal nerve fiber layer (RNFL) thinning, particularly in the temporal quadrant (papillomacular bundle). Ganglion cell-inner plexiform layer (GC-IPL) analysis shows early thinning before RNFL changes[10].
Visual field testing: Central or cecocentral scotoma typical; automated perimetry documents extent and progression.
Fundus imaging: May show optic disc hyperemia, peripapillary telangiectasia, and vascular tortuosity (early findings that later resolve as atrophy develops).
Genetic testing: mtDNA sequencing for primary LHON mutations; secondary mutations may modify penetrance.
Sadun AA et al. Extensive exploration of the Leber hereditary optic neuropathy (LHON) phenotype. Arch Ophthalmol. 2022. ↩︎
Carelli V et al. Retinal ganglion cell neurodegeneration in mitochondrial disorders. Neurobiol Dis. 2019. ↩︎
Yu-Wai-Man P et al. Leber hereditary optic neuropathy. GeneReviews. 2016. ↩︎
Baracca A et al. SDHAF1 mutations in Leigh syndrome. Biochim Biophys Acta. 2018. ↩︎
Lin CS et al. The role of apoptosis in LHON. Neurochem Res. 2019. ↩︎
Hudson G et al. X-inactivation in females with Leber hereditary optic neuropathy. Brain. 2005. ↩︎
Maresca A et al. Vascular and neuronal pathology in mitochondrial optic neuropathies. Acta Neuropathol Commun. 2019. ↩︎
Klopstock T et al. Idebenone in Leber hereditary optic neuropathy: RHODOS trial results. Brain. 2011. ↩︎
Newman NJ et al. Gene therapy for Leber hereditary optic neuropathy. J Neuroophthalmol. 2022. ↩︎
Savini G et al. Optical coherence tomography in Leber hereditary optic neuropathy. Ophthalmology. 2020. ↩︎